



Clinical science

Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a *post hoc* analysis of data from the ADVOCATE trial

Duvuru Geetha ^{1,*}, Christian Pagnoux ², Sebastian E. Sattui ³, Peter A. Merkel ^{4,5}, Maria Weiner ⁶, Juliana Draibe ⁷, Stanislas Faguer ⁸, Sarah Bray ⁹, Rachel E. Gurlin ¹⁰, Monica Balcells-Oliver ¹¹, Annette Bruchfeld ^{6,12}, David R. Jayne ¹³,
ADVOCATE Study Group[†]

¹Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

²Division of Rheumatology, Vasculitis Clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA

⁴Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA

⁵Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA

⁶Department of Nephrology and Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden

⁷Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

⁸Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France

⁹Biostatistics, Amgen Ltd, Cambridge, UK

¹⁰Medical Affairs, Amgen Inc, Thousand Oaks, CA, USA

¹¹Global Medical Affairs, CSL Vifor, Zurich, Switzerland

¹²Department of Renal Medicine, Karolinska University Hospital, CLINTEC Karolinska Institutet, Stockholm, Sweden

¹³Department of Medicine, University of Cambridge, Cambridge, UK

*Correspondence to: Duvuru Geetha, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, 301 Mason Lord Dr, Rm 2509, Baltimore, MD 21224, USA. E-mail: dgeetha1@jhmi.edu

[†]See [supplementary material](#) available at *Rheumatology* online for a list of the ADVOCATE Study Group.

Abstract

Objectives: To evaluate the efficacy and safety of avacopan in patients aged ≥ 65 years with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the phase 3 ADVOCATE trial of avacopan vs a prednisone taper, plus either rituximab or cyclophosphamide.

Methods: In this descriptive, *post hoc* analysis, patients receiving avacopan or a prednisone taper were stratified by age. Key efficacy outcomes included the rate of remission at week 26 and sustained remission at week 52.

Results: Of 160 patients aged ≥ 65 , 109 were aged 65–74 and 51 were ≥ 75 . Remission at week 26 was achieved in 71.7% vs 69.4% of patients aged 65–74 and 73.1% vs 72.0% aged ≥ 75 in the avacopan vs prednisone taper groups, respectively. Sustained remission at week 52 was observed in 65.0% vs 55.1% of patients aged 65–74 and 65.4% vs 56.0% aged ≥ 75 . Relapse rates in the avacopan vs prednisone taper groups were 12.3% vs 18.8% and 3.8% vs 20.8% in the 65–74 and ≥ 75 subgroups, respectively. Improvements in estimated glomerular filtration rate and health-related quality of life were observed in both treatment groups. Use of avacopan compared with a prednisone taper was associated with a 61% and 49% reduction in mean glucocorticoid dose in the 65–74 and ≥ 75 subgroups, respectively, and lower glucocorticoid toxicity. The proportions of patients with adverse events were similar between treatment groups within each age subgroup.

Conclusion: These data support the efficacy and safety of an avacopan-based regimen to treat patients with GPA or MPA aged ≥ 65 .

Keywords: AAV, MPA, GPA, age, avacopan.

Rheumatology key messages

- Patients with GPA or MPA aged ≥ 65 years have a high risk of glucocorticoid-related adverse effects and complications
- Avacopan showed similar efficacy and safety results in patients aged ≥ 65 years compared with those aged < 65 years
- This analysis supports the use of an avacopan-based regimen in older patients with GPA or MPA to minimize glucocorticoid-related risks

Received: 4 December 2024. Accepted: 7 February 2025

© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is characterized by inflammation and damage of small- to medium-sized blood vessels [1]. The most common AAV subtypes are granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) [1]. Although GPA and MPA have been described in all age groups, their incidence increases with age, with rates peaking in patients ≥ 65 years [2–4]. The disease type and pattern of organ involvement seen in patients with AAV differs with age [5, 6]. For example, patients ≥ 65 years of age at diagnosis display more kidney involvement and a higher risk of worsening kidney function compared with younger adults [6, 7]. Patients aged ≥ 65 years at diagnosis also present with higher rates of MPA and myeloperoxidase (MPO)-ANCA positivity compared with patients aged < 65 years [6]. Compared with younger patients, older patients with AAV, especially those aged ≥ 75 years, tend to have more comorbidities, including hypertension, diabetes mellitus, heart disease and malignancy [8, 9] and a greater risk of death within the first 6 months after diagnosis of GPA or MPA [10, 11], mainly due to infection [11–14]. Generally, increased morbidity and mortality are seen in older patients (aged 66–90 years) with GPA or MPA compared with younger patients [8, 15]. The use of induction therapy has a survival benefit in older adults with AAV [8, 16]; however, differences in the treatment of older adults have been observed [11]. Results from one study suggested a lower risk of disease relapse in patients with GPA or MPA ≥ 75 years compared with patients aged 65–75 years [17].

Glucocorticoids (GCs) remain central to remission induction regimens for AAV [18, 19]. The relapsing and remitting nature of AAV means that patients are likely to experience repeated treatment courses and, therefore, high cumulative exposure to GCs [20]. The adverse effects of therapy with GCs are well documented and include infections, osteoporosis, cataracts, gastrointestinal effects, weight gain and diabetes mellitus [21–23]. Furthermore, GCs are major contributors to impaired quality of life [24, 25]. Advances in the treatment of AAV over the past 20 years, including the use of rituximab and combination therapies, have improved patient prognosis [24, 26, 27]. Clinical trials and observational studies demonstrated the success of low-dose GC protocols in achieving remission [28–30]. However, some studies excluded patients aged over 75 or 80 years [8, 31], resulting in an evidence gap in this population at high risk of disease- and treatment-related morbidity and mortality. Minimization of the use of GCs to avoid the toxicity associated with these agents is a focus of treatment [32]. While a low-dose GC regimen seems favourable for the treatment of patients with GPA or MPA aged ≥ 65 years in terms of reduced rates of infection [33–35], improved survival [16] and lower rates of serious adverse events (SAEs) [36], older adults are commonly underrepresented in clinical trials.

Avacopan is an orally administered small-molecule complement C5a receptor (C5aR1) antagonist that selectively blocks the effects of C5a through the C5aR1, including blocking neutrophil chemoattraction and activation [37]. In the phase 3 ADVOCATE trial of avacopan, there was no exclusion criterion for maximum participant age, presenting an opportunity to investigate disease presentation and treatment response in a clinical trial among patients aged ≥ 65 years [37]. The aim of this analysis was to evaluate the efficacy and

safety of avacopan compared with a prednisone taper in three subgroups of patients stratified by age (< 65 years, 65–74 years and ≥ 75 years) in the ADVOCATE trial, with a focus on those aged ≥ 65 years.

Methods

Study design and participants

ADVOCATE was a 52-week, double-blind, randomized, active-controlled trial in patients with GPA or MPA [37]. The study design and complete inclusion and exclusion criteria of ADVOCATE (NCT02994927) have been described previously [37]. 331 patients were enrolled across 143 centres and randomized to receive 30 mg of avacopan twice daily orally plus prednisone-matching placebo, or a tapering oral regimen of prednisone plus avacopan-matching placebo in a double-dummy design. Patients were randomly assigned in a 1:1 ratio to treatment groups and stratified by disease status (newly diagnosed vs relapsing), ANCA status (anti-proteinase 3 [PR3] vs anti-MPO) and standard-of-care induction treatment (rituximab or cyclophosphamide), which all patients received. The trial was performed in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Ethics committees and institutional review boards at participating sites approved the research protocol. All patients gave written informed consent before study entry.

Outcomes and analysis

This analysis reports on the efficacy and safety of avacopan compared with a prednisone taper in the modified intention-to-treat population in subgroups of patients aged < 65 years ($n = 170$), 65–74 years ($n = 109$) and ≥ 75 years ($n = 51$). Baseline characteristics, including disease status and presentation, were assessed. Remission was defined by a BVAS of 0 and no GC use for vasculitis in the preceding 4 weeks. The key efficacy outcomes evaluated were rate of remission at week 26 and sustained remission at week 52. Patients were not considered to be in sustained remission if they had remission at week 26 but a relapse thereafter; relapse was defined as a return of vasculitis activity based on BVAS with one or two minor items for at least two consecutive trial visits, ≥ 1 major item, or ≥ 3 minor items. An exploratory outcome was the rate of relapse at any time after a BVAS of 0 was first achieved. Kidney function was assessed by least squares mean (LSM) change from baseline in estimated glomerular filtration rate (eGFR) in patients with kidney involvement (based on BVAS) and an early change in urinary albumin-to-creatinine ratio (UACR) from baseline to week 4 in patients with kidney involvement (based on BVAS) and a UACR ≥ 10 mg/g creatinine at baseline. Total all-source GC dose, Glucocorticoid Toxicity Index (GTI) Cumulative Worsening Score (CWS) and GTI Aggregate Improvement Score (AIS) were evaluated. Higher GTI-CWS and GTI-AIS indicate more severe toxic effects. Health-related quality of life (HRQoL) was assessed using the Medical Outcomes Study Short Form 36 (SF-36) version 2 physical and mental component summary scores (PCS and MCS) and the EuroQol group 5-Dimension 5-Level (EQ-5D-5L) index score and visual analogue scale (VAS). For all HRQoL instruments, higher scores indicate better quality of life. Safety outcomes included the occurrence of all adverse events (AEs), including those possibly related to GCs or infection.

Statistical analysis

This study was a descriptive analysis reporting means and 95% CIs. The key efficacy analyses were conducted in the modified intention-to-treat population, defined as all randomly assigned patients who received at least one dose of trial medication. Summary score estimates of the common difference in the incidences of remission were calculated with the use of inverse-variance stratum weights. Missing end point data at week 26 and week 52 were imputed as no remission. Data were analysed after all patients had completed the 52-week treatment period, and no interim analyses were performed. LSMs, standard errors and CIs were calculated using models incorporating treatment group, visit, treatment-by-visit interaction and stratification factors as covariates. Longitudinal measurements from the same patients were considered as repeated-measure units in the model. The trial was not powered to draw definitive conclusions from these subgroup analyses.

Results

Baseline demographics, characteristics and comorbidities

Baseline demographics and clinical characteristics of patients treated with avacopan were generally similar to those treated with prednisone taper within all age subgroups (Table 1). There was a trend of mean baseline body mass index (BMI) decreasing in the older age groups, with the lowest mean baseline BMI in the ≥ 75 years subgroup. MPO-ANCA positivity at baseline was more frequent in the 65–74 years and ≥ 75 years subgroups. Relapsing disease at baseline was more frequent in the < 65 years subgroup. The frequency of comorbidities at baseline was higher in the 65–74 and ≥ 75 years subgroups than in the < 65 years subgroup for the majority of comorbidities (Supplementary Table S1, available at *Rheumatology* online). By system organ class, the most frequently occurring comorbidities in the < 65 years subgroup were respiratory, thoracic and mediastinal disorders, occurring in 108 (63.5%) patients. In the 65–74 and ≥ 75 years subgroups, vascular disorders were the most frequently occurring comorbidities, present in 82 (75.2%) and 37 (72.5%) patients, respectively.

Remission and relapse rates

When evaluated by age, the rates of remission were similar to the overall trial results [37]. Across all age subgroups and treatment groups, between 69.4% and 73.1% of patients achieved remission at week 26 (Table 2). Sustained remission at week 52 was observed in 54.4–66.3% of patients across all age subgroups, with a higher percentage achieved in the avacopan group within each age subgroup (percentage difference between treatment groups: < 65 years, 11.8% [95% CI: -2.8, 26.4]; 65–74 years, 9.9% [95% CI: -8.5, 28.3]; ≥ 75 years, 9.4% [95% CI: -17.3, 36.1]). Relapse rates in the avacopan vs prednisone taper groups were 12.3% vs 18.8% and 3.8% vs 20.8% in the 65–74 years and ≥ 75 years subgroups, respectively.

Change in eGFR and UACR

Baseline eGFR in patients with kidney disease (based on BVAS) was lower in the older age subgroups (Table 1). Change in eGFR increased over the 52-week study period in every age

subgroup and both treatment groups (Fig. 1). The largest LSM change from baseline was seen in patients ≥ 75 years treated with avacopan at week 52: 10.7 ± 1.7 mL/min/1.73 m² (baseline eGFR: 25.9 ± 10.3 mL/min/1.73 m²) vs 7.8 ± 1.7 mL/min/1.73 m² with a prednisone taper (baseline eGFR: 30.8 ± 16.5 mL/min/1.73 m²) (LSM difference: 2.9; 95% CI: -1.8, 7.7) (Fig. 1C). The LSM difference at week 52 in the 65–74 years subgroup was -0.8; 95% CI -5.1, 3.4 and 6.4; 95% CI: 1.6, 11.1 in the < 65 years subgroup. The early reduction in UACR observed at week 4 in patients with kidney involvement (based on BVAS) and a UACR ≥ 10 mg/g creatinine in the avacopan group is shown in Table 2.

GC dose and toxicity

The total all-source median GC dose at week 52 was approximately five-fold higher in the prednisone taper group than in the avacopan group within all three age subgroups (Table 2). Total all-source mean GC dose from day 0 to week 52 was decreased in the avacopan group by 55%, 61% and 49% for the < 65 years, 65–74 years and ≥ 75 years subgroups, respectively. GTI-CWS was also higher in the prednisone taper group than in the avacopan group across all age subgroups (Table 2), with an LSM (95% CI) difference between groups (avacopan vs prednisone taper) of -20.1 (-32.0, -8.1) in the < 65 years age subgroup, -10.3 (-27.2, 6.7) in the 65–74 years subgroup and -18.3 (-40.3, 3.7) in the ≥ 75 years subgroup. GTI-AIS (LSM \pm standard error of the mean) at week 26 was particularly low with avacopan (0.4 ± 8.5) compared with a prednisone taper (15.1 ± 9.7) in the ≥ 75 years subgroup. LSM (95% CI) difference between treatment groups in GTI-AIS was -16.9 (-29.6, -4.2), -1.5 (-17.6, 14.6) and -14.7 (-35.6, 6.2) in the < 65 years, 65–74 years and ≥ 75 years subgroups, respectively.

HRQoL outcomes

Results for HRQoL outcomes at week 52, as measured by the SF-36 PCS and MCS scores, EQ-5D-5L VAS and EQ-5D-5L index score are shown in Fig. 2. At week 52, change from baseline in HRQoL was generally higher in the avacopan group than in the prednisone taper group across most age subgroups, except the SF-36 MCS in the ≥ 75 years subgroup.

Safety outcomes

The proportions of AEs and SAEs were broadly similar between treatment groups within each age subgroup (Table 3). In the avacopan and prednisone taper groups, respectively, hepatic enzymes increased in 1 (1.3%) vs 5 (5.6%) patients aged < 65 years, 1 (1.7%) vs 1 (2%) patients aged 65–74 years, and 3 (11.5%) vs 1 (4.0%) patients aged ≥ 75 years; cardiac disorders occurred in 9 (11.3%) vs 7 (7.8%) patients in the < 65 years subgroup, 13 (21.7%) vs 8 (16.3%) patients in the 65–74 years subgroup and 4 (15.4%) vs 6 (24%) patients in the ≥ 75 years subgroup; and neoplasms benign, malignant and unspecified (including cysts and polyps) occurred in 3 (3.8%) vs 7 (7.8%) patients aged < 65 years, 1 (1.7%) vs 7 (14.3%) patients aged 65–74 years and 2 (7.7%) vs 2 (8%) patients aged ≥ 75 years.

Discussion

This *post hoc* subgroup analysis from the ADVOCATE trial demonstrates that avacopan when added to standard-of-care immunosuppression, is equally effective compared with a

Table 1. Baseline characteristics of patients with GPA or MPA in the ADVOCATE trial of avacopan, stratified by age

| Baseline characteristic | Age <65 years | | | Age 65–74 years | | | Age ≥75 years | | |
|---|----------------------|---------------------------------|--------------------|----------------------|---------------------------------|--------------------|----------------------|---------------------------------|-------------------|
| | Avacopan (n = 80) | Prednisone taper (n = 90) | Total (n = 170) | Avacopan (n = 60) | Prednisone taper (n = 49) | Total (n = 109) | Avacopan (n = 26) | Prednisone taper (n = 25) | Total (n = 51) |
| Sex, n (%) | | | | | | | | | |
| Male | 53 (66.3) | 54 (60.0) | 107 (62.9) | 32 (53.3) | 22 (44.9) | 54 (49.5) | 13 (50.0) | 12 (48.0) | 25 (49.0) |
| Female | 27 (33.8) | 36 (40.0) | 63 (37.1) | 28 (46.7) | 27 (55.1) | 55 (50.5) | 13 (50.0) | 13 (52.0) | 26 (51.0) |
| Race, n (%) | | | | | | | | | |
| Asian | 3 (3.8) | 6 (6.7) | 9 (5.3) | 5 (8.3) | 3 (6.1) | 8 (7.3) | 9 (34.6) | 6 (24.0) | 15 (29.4) |
| White | 69 (86.3) | 77 (85.6) | 146 (85.9) | 52 (86.7) | 44 (89.8) | 96 (88.1) | 17 (65.4) | 19 (76.0) | 36 (70.6) |
| Other ^a | 8 (10) | 7 (7.8) | 15 (8.8) | 3 (5.0) | 2 (4.1) | 5 (4.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| BMI (kg/m ²), mean (s.d.) | 27.2 (6.2) | 27.6 (5.3) | 27.4 (5.7) | 27.1 (6.3) | 26.6 (4.7) | 26.8 (5.6) | 24.6 (3.9) | 24.4 (5.2) | 24.5 (4.6) |
| Type of AAV, n (%) | | | | | | | | | |
| GPA | 48 (60.0) | 60 (66.7) | 108 (63.5) | 33 (55.0) | 22 (44.9) | 55 (50.5) | 10 (38.5) | 8 (32.0) | 18 (35.3) |
| MPA | 32 (40.0) | 30 (33.3) | 62 (36.5) | 27 (45.0) | 27 (55.1) | 54 (49.5) | 16 (61.5) | 17 (68.0) | 33 (64.7) |
| AAV status, n (%) | | | | | | | | | |
| Newly diagnosed | 49 (61.3) | 56 (62.2) | 105 (61.8) | 45 (75.0) | 38 (77.6) | 83 (76.1) | 21 (80.8) | 20 (80.0) | 41 (80.4) |
| Relapsed | 31 (38.8) | 34 (37.8) | 65 (38.2) | 15 (25.0) | 11 (22.4) | 26 (23.9) | 5 (19.2) | 5 (20.0) | 10 (19.6) |
| ANCA positivity, n (%) | | | | | | | | | |
| PR3-ANCA | 43 (53.8) | 53 (58.9) | 96 (56.5) | 22 (36.7) | 15 (30.6) | 37 (33.9) | 7 (26.9) | 2 (8.0) | 9 (17.6) |
| MPO-ANCA | 37 (46.3) | 37 (41.1) | 74 (43.5) | 38 (63.3) | 34 (69.4) | 72 (66.1) | 19 (73.1) | 23 (92.0) | 42 (82.4) |
| Duration of AAV (months), mean (s.d.) | 32.0 (67.3) | 26.0 (45.9) | 28.8 (56.9) | 16.5 (34.9) | 12.5 (26.4) | 14.7 (31.3) | 9.7 (20.5) | 14.0 (40.4) | 11.8 (31.6) |
| Standard-of-care treatment, n (%) | | | | | | | | | |
| IV rituximab | 57 (71.3) | 57 (63.3) | 114 (67.1) | 34 (56.7) | 34 (69.4) | 68 (62.4) | 16 (61.5) | 16 (64.0) | 32 (62.7) |
| IV cyclophosphamide | 20 (25.0) | 31 (34.4) | 51 (30.0) | 22 (36.7) | 12 (24.5) | 34 (31.2) | 9 (34.6) | 8 (32.0) | 17 (33.3) |
| Oral cyclophosphamide | 3 (3.8) | 2 (2.2) | 5 (2.9) | 4 (6.7) | 3 (6.1) | 7 (6.4) | 1 (3.8) | 1 (4.0) | 2 (3.9) |
| BVAS score, mean (s.d.) | 15.6 (5.7) | 15.3 (5.5) | 15.5 (5.6) | 16.6 (5.5) | 16.5 (5.9) | 16.6 (5.7) | 17.8 (7.1) | 18.4 (5.6) | 18.1 (6.3) |
| VDI score, mean (s.d.) | 0.6 (1.3) | 0.8 (1.4) | 0.7 (1.3) | 0.8 (1.9) | 0.6 (1.3) | 0.7 (1.7) | 0.6 (1.4) | 0.5 (1.7) | 0.6 (1.5) |
| Kidney disease at baseline, n (%) | 65 (81.3) | 68 (75.6) | 133 (78.2) | 49 (81.7) | 43 (87.8) | 92 (84.4) | 20 (76.9) | 23 (92.0) | 43 (84.3) |
| eGFR (mL/min/1.73 m ²), mean (s.d.) ^b | 53.9 (31.1) | 53.1 (31.8) | 53.5 (31.5) | 40.2 (22.7) | 41.5 (19.2) | 40.8 (21.1) | 25.9 (10.3) | 30.8 (16.5) | 28.5 (14.0) |
| UACR (mg/g), geometric mean ^c | 495.7 | 347.3 | 417.4 | 393.4 | 290.6 | 346.2 | 360.0 | 258.1 | 305.3 |

Data were missing for two patients for BMI, two patients for VDI and four patients for eGFR. UACR data were missing for 77 patients.

^a Other race included Black or African American, multiple or other races.

^b eGFR is reported in patients with kidney disease (based on BVAS) at baseline.

^c UACR is reported in patients with kidney disease at baseline (based on BVAS) and albuminuria (UACR ≥10 mg/g creatinine).

AAV: ANCA-associated vasculitis; eGFR: estimated glomerular filtration rate; GPA: granulomatosis with polyangiitis; IV: intravenous; MPA: microscopic polyangiitis; MPO: myeloperoxidase; PR3: proteinase 3; UACR: urine albumin-to-creatinine ratio; VDI: Vasculitis Damage Index.

Table 2. Key efficacy endpoints in patients with GPA or MPA in the ADVOCATE trial of avacopan, stratified by age

| Outcome | Age <65 years (n = 170) | | Age 65–74 years (n = 109) | | Age ≥75 years (n = 51) | |
|---|-------------------------|------------------------------|---------------------------|------------------------------|------------------------|------------------------------|
| | Avacopan (n = 80) | Prednisone taper (n = 90) | Avacopan (n = 60) | Prednisone taper (n = 49) | Avacopan (n = 26) | Prednisone taper (n = 25) |
| Remission at week 26, n (%) | 58 (72.5) | 63 (70.0) | 43 (71.7) | 34 (69.4) | 19 (73.1) | 18 (72.0) |
| Difference between treatment groups (%) [two-sided 95% CI] | 2.5 [−11.1, 16.1] | | 2.3 [−14.9, 19.5] | | 1.1 [−23.4, 25.6] | |
| Sustained remission at week 52, n (%) | 53 (66.3) | 49 (54.4) | 39 (65.0) | 27 (55.1) | 17 (65.4) | 14 (56.0) |
| Difference between treatment groups (%) [two-sided 95% CI] | 11.8 [−2.8, 26.4] | | 9.9 [−8.5, 28.3] | | 9.4 [−17.3, 36.1] | |
| Relapse rate, ^a n (%) | 8 (10.7) | 19 (22.4) | 7 (12.3) | 9 (18.8) | 1 (3.8) | 5 (20.8) |
| Hazard ratio [95% CI] | 0.52 [0.18, 1.53] | | 0.64 [0.24, 1.72] | | 0.18 [0.02, 1.53] | |
| UACR percent change at week 4, ^b LSM ± s.e.m. | −45 ± 14 | 15 ± 14 | −34 ± 16 | −19 ± 17 | −33 ± 26 | −8 ± 25 |
| LSM difference [95% CI] | −52 [−67, −31] | | −19 [−47, 23] | | −28 [−62, 37] | |
| GTI-CWS at week 26, LSM ± s.e.m. | 40.2 ± 4.8 | 60.3 ± 4.4 | 43.4 ± 6.3 | 53.6 ± 7.2 | 33.1 ± 8.8 | 51.4 ± 10.1 |
| LSM difference [95% CI] | −20.1 [−32.0, −8.1] | | −10.3 [−27.2, 6.7] | | −18.3 [−40.3, 3.7] | |
| GTI-AIS at week 26, LSM ± s.e.m. | 13.7 ± 5.1 | 30.5 ± 4.6 | 13.6 ± 5.9 | 15.1 ± 6.8 | 0.4 ± 8.5 | 15.1 ± 9.7 |
| LSM difference [95% CI] | −16.9 [−29.6, −4.2] | | −1.5 [−17.6, 14.6] | | −14.7 [−35.6, 6.2] | |
| Total all-source GC dose, mg (mean/median) | 1861/620 | 4122/3230 | 1410/575 | 3579/3055 | 1718/588 | 3382/2840 |

^a Relapse rates are based on the number of patients who achieved a BVAS of 0 after any time during the 52-week treatment period.

^b UACR is reported in patients with kidney involvement (based on BVAS at baseline) and baseline UACR ≥10 mg/g creatinine.

AIS: Aggregate Improvement Score; CWS: Cumulative Worsening Score; GC: glucocorticoid; GPA: granulomatosis with polyangiitis; GTI: Glucocorticoid Toxicity Index; LSM: least squares mean; MPA: microscopic polyangiitis; UACR: urine albumin-to-creatinine ratio.




Figure 1. eGFR during a 52-week treatment period in patients with GPA or MPA in the ADVOCATE trial. (A–C) Change in eGFR from baseline in patients aged <65, 65–74 and ≥75 years, respectively. (D) Mean ± s.e.m. eGFR at baseline and week 52 in patients aged <65, 65–74 and ≥75 years. eGFR was assessed only in patients with kidney involvement (based on BVAS) at baseline. eGFR: estimated glomerular filtration rate; LSM: least squares mean; MPA: microscopic polyangiitis




Figure 2. Health-related quality of life outcomes of (A) SF-36 physical component summary score, (B) SF-36 mental component summary score, (C) EQ-5D-5L VAS and (D) EQ-5D-5L index score at week 52 in patients with GPA or MPA stratified by age treated with avacopan or a prednisone taper. EQ-5D-5L: EuroQol 5-Dimension 5-Level; GPA: granulomatosis with polyangiitis; LSM: least squares mean; MPA: microscopic polyangiitis; SF-36: Short Form-36; VAS: visual analogue scale

prednisone taper for the treatment of GPA or MPA with respect to remission at week 26, and more effective for sustained remission at week 52 in patients aged ≥ 65 years. Avacopan was also associated with a greater improvement in HRQoL compared with a prednisone taper in patients aged ≥ 65 years. These results are consistent with those from the < 65 years subgroup. In addition, the proportion of AEs and SAEs was broadly similar between treatment groups within the 65–74 years and ≥ 75 years subgroups, as in the < 65 years subgroup. The addition of avacopan to the standard of care in the treatment of older adults (≥ 65 years) with GPA or MPA is associated with efficacy and safety similar to that observed in younger adults and should be considered in this older population, who remain at higher risk of poor outcomes.

Efficacy and safety outcomes in the avacopan group of the 65–74 years and ≥ 75 years subgroups were achieved with an $\sim 80\%$ reduction in median overall total GC dose compared with the prednisone taper group. The marked reduction in the use of GCs in the avacopan treatment group was per the study protocol and is among the key benefits of the avacopan-based treatment regimen. This outcome would

likely be particularly beneficial for older patients, who are more susceptible to adverse effects of GCs [36]. Notably, the GTI-AIS was reduced with avacopan compared with a prednisone taper in the ≥ 75 years subgroup.

A high proportion of patients aged 65–74 years and ≥ 75 years in this study presented with kidney involvement (based on BVAS) at baseline ($\sim 84\%$), and among those patients, mean baseline eGFR was lower in the ≥ 75 years subgroup compared with the 65–74 years and the < 65 years subgroups. This observation is consistent with previous studies showing that GPA or MPA is more likely to present with more serious kidney involvement in patients aged ≥ 65 years than in younger patients [6, 7]. This analysis demonstrates that avacopan is associated with improved kidney function in patients aged ≥ 75 years. However, it is important to note that the difference between treatment groups in change in eGFR throughout treatment was larger in the < 65 years subgroup than in the two older subpopulations. Reasons for this may include age-related decline in eGFR, higher rates of comorbidities at baseline, or a higher proportion of MPO-ANCA positivity in older patients than in the < 65 years

Table 3. Safety results in patients with GPA or MPA treated with avacopan or prednisone taper, stratified by age

| Outcome | Age <65 years (n = 170) | | Age 65–74 years (n = 109) | | Age ≥75 years (n = 51) | |
|--|-------------------------|---------------------------|---------------------------|---------------------------|--------------------------|---------------------------|
| | Avacopan (n = 80) | Prednisone taper (n = 90) | Avacopan (n = 60) | Prednisone taper (n = 49) | Avacopan (n = 26) | Prednisone taper (n = 25) |
| Total AEs, n (%) patients, n events | 79 (98.8) 883 events | 88 (97.8) 1140 events | 59 (98.3) 623 events | 48 (98.0) 681 events | 26 (100.0) 273 events | 25 (100.0) 318 events |
| AEs possibly related to GCs, n (%) patients, n events | 53 (66.3) 198 events | 70 (77.8) 269 events | 30 (50.0) 124 events | 41 (83.7) 164 events | 24 (92.3) 73 events | 20 (80.0) 105 events |
| Any AE related to infection, n (%) patients, n events | 53 (66.3) 105 events | 66 (73.3) 163 events | 40 (66.7) 86 events | 38 (77.6) 88 events | 20 (76.9) 42 events | 20 (80.0) 40 events |
| Total SAEs, n (%) patients, n events | 28 (35.0) 51 events | 38 (42.2) 81 events | 25 (41.7) 43 events | 22 (44.9) 51 events | 17 (65.4) 22 events | 14 (56.0) 34 events |
| SAEs possibly related to GCs, n (%) patients, n events | 4 (5.0) 5 events | 16 (17.8) 18 events | 7 (11.7) 8 events | 4 (8.2) 7 events | 5 (19.2) 5 events | 7 (28.0) 11 events |
| Any SAE related to infection, n (%) patients, n events | 7 (8.8) 8 events | 14 (15.6) 17 events | 11 (18.3) 13 events | 5 (10.2) 6 events | 4 (15.4) 4 events | 6 (24.0) 8 events |
| Hospitalization possibly related to study medication, n (%) patients, n events | 4 (5.0) 5 events | 11 (12.2) 13 events | 5 (8.3) 6 events | 4 (8.2) 8 events | 5 (19.2) 5 events | 5 (20.0) 7 events |
| Deaths, n (%) patients | 0 (0.0) | 2 (2.2) | 2 (3.3) | 2 (4.1) | 0 (0.0) | 0 (0.0) |

AE: adverse event; GC: glucocorticoid; SAE: serious adverse event.

subgroup, which may indicate increased presence of subclinical disease during years before diagnosis and kidney fibrosis. These characteristics may also contribute to a low eGFR at baseline, worse kidney recovery and persistence of elevated UACR after treatment.

AAV is associated with reductions in HRQoL [38–42]. In the current analysis, the change in EQ-5D-5L VAS score from baseline to the end of treatment was larger in the avacopan vs prednisone taper group in all age subgroups (Fig. 2), as was previously reported in the analysis of HRQoL in the ADVOCATE trial [42]. The LSM difference between treatment groups at week 52 was largest in the ≥75 years subgroup for SF-36 PCS score and EQ-5D-5L VAS. These data show that incorporation of avacopan into the management strategies of patients with GPA or MPA aged ≥65 years could improve the quality of life in these patients.

Avacopan is included in the Kidney Disease Improving Global Outcomes (KDIGO) 2024 clinical practice guideline for the management of AAV and the 2022 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of GPA or MPA [19, 43]. The KDIGO guideline states that ‘avacopan may be used as an alternative to glucocorticoids. Patients with an increased risk of glucocorticoids toxicity are likely to receive the most benefit from avacopan. Patients with lower GFR may benefit from greater GFR recovery’ [43]. According to the EULAR recommendations, avacopan, used in combination with rituximab or cyclophosphamide, may be considered for induction of remission in GPA or MPA as part of a strategy to substantially reduce exposure to GCs. These recommendations include implementing individualized treatment strategies based on the patient’s disease course, presentation and comorbidities [19]. Clinicians could consider incorporating avacopan into the treatment regimens of patients at the highest risk of GC-related adverse effects and complications (such as osteoporosis, cataracts and GC-induced diabetes mellitus [21–23, 44]) or patients with severe kidney involvement. Emerging data regarding relevant risk factors (e.g. frailty) in this age group will better inform treatment in older adults and personalize the management of these patients [11, 45]. Based on the results from this analysis, avacopan may play a role in defining patient-tailored therapeutic strategies in patients with

GPA or MPA aged ≥65 years at high risk of GC-related toxicity.

This analysis has several strengths, including the inclusion of data derived from a randomized trial and the use of defined outcomes of importance to clinicians and patients. This analysis also demonstrated the importance and value of including older patients in clinical trials. The limitations of this study include the relatively small sample size of the subpopulations discussed, increasing the probability of a type I error and potentially limiting the ability to generalize the findings, and the *post hoc* nature of the analysis. The conclusions based on kidney involvement are limited because the eligibility criteria from the original trial excluded patients with eGFR <15 mL/min/1.73 m².

Conclusions

This analysis from the ADVOCATE trial of patients stratified by age demonstrated similar trends of efficacy and safety of avacopan in patients aged ≥65 years as in patients aged <65 years, including improvements in measures of HRQoL and reductions in GC-related toxicities. These results highlight the efficacy and safety of an avacopan-based regimen, with minimization of GC use, in addition to rituximab or cyclophosphamide, for induction of remission in patients with GPA or MPA aged ≥65 years.

Supplementary material

Supplementary material is available at *Rheumatology* online.

Data availability

Data are available on reasonable request from qualified external scientific and medical researchers and based on an appropriate scientific rationale/analysis plan. Please contact phase4@viforpharma.com.

Funding

Funding for the ADVOCATE study was provided by ChemoCentryx (a wholly owned subsidiary of Amgen).

Disclosure statement: D.G. reports consultant fees from Amgen, ChemoCentryx (a wholly owned subsidiary of Amgen), Aurinia, Otsuka, Calliditas, Vera Therapeutics and GlaxoSmithKline (GSK). C.P. reports consultant fees from Otsuka and AstraZeneca and speaker fees from Otsuka and GSK. S.E.S. reports grants from the Rheumatology Research Foundation and Bristol Myers Squibb Foundation, research support from AstraZeneca and GSK, consultant fees from Sanofi (all funds toward research support), speaker fees from Fresenius Kabi (all funds toward research support), travel support from the National Center for Advancing Transitional Sciences and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and advisory board participation for Amgen and Sanofi (all funds toward research support). P.A.M. reports royalties from UpToDate; consultant fees from AbbVie, Alpine, Amgen, Argenx, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, CSL Behring, GSK, HiBio, iCell, InflaRx, Janssen, Kinevant, Kyverna, Metagenomia, Novartis, NS Pharma, Q32 Bio, Regeneron, Sanofi, Sparrow, Takeda and Visterra; stock options for Kyverna, Q32 Bio and Sparrow; and grants to his institution from AbbVie, Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Eicos, Electra, Forbius, Genentech/Roche, GSK, InflaRx, Neutrolis and Takeda. M.W. reports consultant fees from CSL Vifor, speaker fees from CSL Vifor and AstraZeneca, and grants to her institution from the Swedish Kidney Foundation and the Swedish Medical Society. J.D. reports grants from CSL Vifor, speaker fees from Alexion and CSL Vifor, funding for educational programmes or training activities from Alexion, travel support from CSL Vifor, and advisory board participation for CSL Vifor. S.F. reports consultant fees from Novartis SA, Abionyx Pharma and CSL Vifor; speaker fees from CSL Vifor and Baxter, travel support from Alexion and CSL Vifor, and advisory board participation for Sanofi-Genzyme and CSL Vifor. S.B. is an employee of Amgen and owns Amgen shares. R.E.G. is an employee of Amgen. M.B. is an employee of CSL Vifor and owns Amgen and CSL Vifor shares. A.B. reports consultant and speaker fees from Alexion, AstraZeneca, Bayer, Boehringer-Ingelheim, CSL Vifor and GSK; payment for expert testimony from the Swedish National Board of Health and Welfare; and advisory board participation for Alexion. D.R.J. reports consultant fees from AstraZeneca, Amgen, CSL Vifor, Novartis, Roche and Visterra; speaker fees from Amgen and CSL Vifor; advisory board participation for Chinook, GSK and Takeda; stock options for Aurinia and Alentis; and grants to his institution from GSK, CSL Vifor and Roche.

Acknowledgements

The authors are grateful to all the study coordinators, investigators and patients who participated in the ADVOCATE study. Amgen and Vifor Fresenius Medical Care Renal Pharma Ltd supported part of the data analysis for this manuscript. Medical writing support was provided by Scarlett Dell-Cronin and Bryony Brockhurst of Obsidian Healthcare Group Ltd, UK, and funded by Vifor Fresenius Medical Care Renal Pharma Ltd. A portion of the results included in this manuscript were previously presented as an abstract and poster at the American Society of Nephrology Kidney Week 2023 in Philadelphia, PA, USA, 2–5 November 2023 and at

the American College of Rheumatology Convergence 2023 meeting in San Diego, CA, USA, 10–15 November 2023.

References

1. Kitching AR, Anders H-J, Basu N *et al.* ANCA-associated vasculitis. *Nat Rev Dis Primers* 2020;6:71.
2. Mohammad AJ, Jacobsson LTH, Westman KWA *et al.* Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. *Rheumatology* 2009;48:1560–5.
3. Mohammad AJ. An update on the epidemiology of ANCA-associated vasculitis. *Rheumatology* 2020;59:iii42–iii50.
4. Watts RA, Mooney J, Skinner J *et al.* The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis. *Rheumatology* 2012;51:926–31.
5. Bloom JL, Pickett-Nairn K, Silveira L, *et al.* The association between age at diagnosis and disease characteristics and damage in patients with ANCA-associated vasculitis. *Arthritis Rheumatol* 2023;75:2216–27.
6. Monti S, Craven A, Klersy C *et al.*; DCVAS Collaborators. Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. *Rheumatology* 2021;60:617–28.
7. Zhang S, Chen X, Hou Z *et al.* Renal outcomes in older adults with antineutrophil cytoplasmic autoantibody-associated vasculitis: a new prediction model. *Am J Nephrol* 2023;54:399–407.
8. Weiner M, Goh SM, Mohammad AJ *et al.* Outcome and treatment of elderly patients with ANCA-associated vasculitis. *Clin J Am Soc Nephrol* 2015;10:1128–35.
9. Bombach AS, Appel GB, Radhakrishnan J *et al.* ANCA-associated glomerulonephritis in the very elderly. *Kidney Int* 2011;79:757–64.
10. Hoganson DD, From AM, Michet CJ. ANCA vasculitis in the elderly. *J Clin Rheumatol* 2008;14:78–81.
11. Sattui SE, Jiang B, Fu X, *et al.* The effects of age and frailty on the risks of end-stage renal disease, death, and severe infection in older adults with antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study. *Lancet Rheumatol* 2024;6:e771–9.
12. Judge PK, Reschen ME, Haynes R *et al.* Outcomes of elderly patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis treated with immunosuppressive therapy. *Nephron* 2016;133:223–31.
13. Titeca-Beauport D, Francois A, Lobbedez T *et al.* Early predictors of one-year mortality in patients over 65 presenting with ANCA-associated renal vasculitis: a retrospective, multicentre study. *BMC Nephrol* 2018;19:317.
14. Sánchez Álamo B, Moi L, Bajema I *et al.*; EUVAS. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. *Nephrol Dial Transplant* 2023;38:1655–65.
15. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century—a disease of older patients. *Rheumatology* 2005;44:495–501.
16. Morris AD, Elsayed ME, Ponnusamy A *et al.* Treatment outcomes of anti-neutrophil cytoplasmic autoantibody-associated vasculitis in patients over age 75 years: a meta-analysis. *Am J Nephrol* 2020; 51:327–36.
17. Thietart S, Beinse G, Smets P *et al.*; French Vasculitis Study Group. Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: a multicentre cohort study. *J Intern Med* 2022;291:350–63.
18. Chung SA, Langford CA, Maz M *et al.* 2021 American college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheumatol* 2021;73:1366–83.
19. Hellmich B, Sanchez-Alamo B, Schirmer JH *et al.* EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. *Ann Rheum Dis* 2024;83:30–47.

20. Floyd L, Morris AD, Woywodt A *et al.* Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat? *Clinical Kidney J* 2022;15:618–23.
21. Robson J, Doll H, Suppiah R *et al.* Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. *Ann Rheum Dis* 2015;74:177–84.
22. Weiner M, Goh SM, Mohammad AJ *et al.* Effect of treatment on damage and hospitalization in elderly patients with microscopic polyangiitis and granulomatosis with polyangiitis. *J Rheumatol* 2020;47:580–8.
23. Floyd L, Morris A, Joshi M *et al.* Glucocorticoid therapy in ANCA vasculitis: using the glucocorticoid toxicity index as an outcome measure. *Kidney* 2021;2:1002–10.
24. Almaani S, Fussner LA, Brodsky S *et al.* ANCA-associated vasculitis: an update. *J Clin Med* 2021;10:1446.
25. Black RJ, Robson JC, Goodman SM *et al.* A patient-reported outcome measure for effect of glucocorticoid therapy in adults with inflammatory diseases is needed: report from the OMERACT 2016 special interest group. *J Rheumatol* 2017;44:1754–8.
26. Arzoun H, Srinivasan M, Thangaraj SR, *et al.* Recent advancements in the management of anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic review. *Cureus* 2022;14:e21814.
27. Samman KN, Ross C, Pagnoux C *et al.* Update in the management of ANCA-associated vasculitis: recent developments and future perspectives. *Int J Rheumatol* 2021;2021:5534851.
28. McAdoo SP, Medjeral-Thomas N, Gopaluni S *et al.* Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. *Nephrol Dial Transplant* 2019;34:63–73.
29. Jones RB, Tervaert JWC, Hauser T, *et al.* Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* 2010;363:211–20.
30. Walsh M, Merkel PA, Peh C-A *et al.*; PEXIVAS Investigators. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. *N Engl J Med* 2020;382:622–31.
31. Jayne DRW, Gaskin G, Rasmussen N, *et al.* Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. *J Am Soc Nephrol* 2007;18:2180–8.
32. Fenoglio R, Roccatello D, Sciascia S. Rituximab, cyclophosphamide, and corticosteroids for ANCA vasculitis: the good, the bad, and the ugly. *Kidney Blood Press Res* 2020;45:784–91.
33. Sada K-E, Ohashi K, Asano Y, *et al.* Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies. *Arthritis Res Ther* 2020;22:236.
34. Furuta S, Nakagomi D, Kobayashi Y, *et al.* Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in anca-associated vasculitis: a randomized clinical trial. *JAMA* 2021;325:2178–87.
35. McGovern D, Williams SP, Parsons K *et al.* Long-term outcomes in elderly patients with ANCA-associated vasculitis. *Rheumatology* 2020;59:1076–83.
36. Pagnoux C, Quéméneur T, Ninet J, *et al.* Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. *Arthritis Rheumatol* 2015;67:1117–27.
37. Jayne DRW, Merkel PA, Schall TJ, *et al.* Avacopan for the treatment of ANCA-associated vasculitis. *N Engl J Med* 2021;384:599–609.
38. Mercuzot C, Letertre S, Daïen CI *et al.* Comorbidities and health-related quality of life in patients with antineutrophil cytoplasmic antibody (ANCA) - associated vasculitis. *Autoimmun Rev* 2021;20:102708.
39. Harper L, Morgan MD, Chanouzas D, *et al.* Treatment of fatigue with physical activity and behavioural change support in vasculitis: study protocol for an open-label randomised controlled feasibility study. *BMJ Open* 2018;8:e023769.
40. Herlyn K, Hellmich B, Seo P *et al.* Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. *Arthritis Care Res (Hoboken)* 2010;62:1639–45.
41. Basu N, Jones GT, Fluck N *et al.* Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. *Rheumatology* 2010;49:1383–90.
42. Strand V, Jayne DRW, Horomanski A, *et al.* The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial. *Lancet Rheumatol* 2023;5:e451–60.
43. Kidney Disease: Improving Global Outcomes (KDIGO); ANCA Vasculitis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis. *Kidney Int* 2024;105:S71–116.
44. Turgeon D, Bakowsky V, Baldwin C *et al.* CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum. *Rheumatology* 2023;62:2646–51.
45. Brix SR, Tesar V. Rituximab in the frail and elderly with severe ANCA-associated GN. *Clin J Am Soc Nephrol* 2022;17:1546–8.